| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175614-100μg | 100μg | In stock | $59.90 | |
| Ab175614-1mg | 1mg | In stock | $279.90 | |
| Ab175614-5mg | 5mg | In stock | $739.90 | |
| Ab175614-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,189.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Ocrelizumab (anti-CD20) - Primary antibody, specific to MS4A1, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | APY antibody | ATOPY antibody | B lymphocyte antigen CD20 antibody | B Lymphocyte Cell Surface Antigen B1 antibody | B-lymphocyte antigen CD20 antibody | B-lymphocyte cell-surface antigen B1 antibody | B-lymphocyte surface antigen B1 antibody | B1 antibod |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | MS4A1 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | BINDING AGENT |
| Mechanism of action | Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1) |
| Product Description | Ocrelizumab (anti-CD20) is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab (anti-CD20) are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab (anti-CD20) is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS). |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145.82 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 637334-45-3 |
Ocrelizumab (anti-CD20) (Ab175614) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ocrelizumab (anti-CD20) (Ab175614). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Ocrelizumab (anti-CD20) (Ab175614) - SEC
The purity of Ocrelizumab (anti-CD20) (Ab175614) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 227 |
|---|---|
| Wikipedia | Ocrelizumab |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0102656 | Certificate of Analysis | Jan 30, 2024 | Ab175614 |
| ZJ24F0102655 | Certificate of Analysis | Jan 30, 2024 | Ab175614 |
| ZJ24F0102654 | Certificate of Analysis | Jan 30, 2024 | Ab175614 |
| 1. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W et al.. (2005) Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.. J Immunother, 28 (3): (212-9). [PMID:15838377] [10.1021/op500134e] |
| 2. Hutas G. (2008) Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.. Curr Opin Investig Drugs, 9 (11): (1206-15). [PMID:18951300] [10.1021/op500134e] |
| 3. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy.. Expert Opin Biol Ther, 9 (7): (889-95). [PMID:19463076] [10.1021/op500134e] |
| 4. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B et al.. (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.. N Engl J Med, 376 (3): (209-220). [PMID:28002688] [10.1021/op500134e] |
| 5. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC. (2014) Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.. J Immunol, 193 (2): (580-586). [PMID:24928997] [10.1021/op500134e] |
| 6. Gingele S, Jacobus TL, Konen FF, Hümmert MW, Sühs KW, Schwenkenbecher P, Ahlbrecht J, Möhn N, Müschen LH, Bönig L et al.. (2018) Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.. Cells, 8 (1): (1755-70). [PMID:30597851] [10.1021/op500134e] |
| 7. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010) CD20 deficiency in humans results in impaired T cell-independent antibody responses.. J Clin Invest, 120 (1): (214-22). [PMID:20038800] [10.1021/op500134e] |
| 8. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.. Clin Cancer Res, 10 (8): (2868-78). [PMID:15102696] [10.1021/op500134e] |
| 9. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al.. (2011) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.. Leukemia, 25 (1): (101-9). [PMID:20975664] [10.1021/op500134e] |
| 10. Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J. (2017) CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.. Oncoimmunology, 7 (1): (e1380142). [PMID:29296544] [10.1021/op500134e] |
| 11. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.. Sci Transl Med, 7 (287): (287ra70). [PMID:25972002] [10.1021/op500134e] |
| 12. Tedder, T F TF, Streuli, M M, Schlossman, S F SF and Saito, H H.. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2448768] |
| 13. Einfeld, D A DA, Brown, J P JP, Valentine, M A MA, Clark, E A EA and Ledbetter, J A JA.. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.. The EMBO journal, [PMID:2456210] |
| 14. Tedder, T F TF, Klejman, G G, Schlossman, S F SF and Saito, H H.. (1989) Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:2466899] |
| 15. Stamenkovic, I I and Seed, B B.. (1988) Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein.. The Journal of experimental medicine, (1): [PMID:3260267] |
| 16. Tedder, T F TF, Boyd, A W AW, Freedman, A S AS, Nadler, L M LM and Schlossman, S F SF.. (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.. Journal of immunology (Baltimore, Md. : 1950), [PMID:3925015] |
| 17. Bubien, J K JK, Zhou, L J LJ, Bell, P D PD, Frizzell, R A RA and Tedder, T F TF.. (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.. The Journal of cell biology, [PMID:7684739] |
| 18. and Goldenberg, D M DM.. () The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.. Critical reviews in oncology/hematology, [PMID:11418316] |
| 19. and Dillman, R O RO.. () Monoclonal antibody therapy for lymphoma: an update.. Cancer practice, [PMID:11879282] |
| 20. . (2003) Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, [PMID:12899647] |
| 21. Li, Haidong H, Ayer, Linda M LM, Lytton, Jonathan J and Deans, Julie P JP.. (2003) Store-operated cation entry mediated by CD20 in membrane rafts.. The Journal of biological chemistry, (24): [PMID:12920111] |
| 22. Du, Jiamu J and 8 more authors.. (2008) Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.. Molecular immunology, [PMID:18346788] |
| 23. Dörner, Thomas T and Burmester, Gerd R GR.. (2008) New approaches of B-cell-directed therapy: beyond rituximab.. Current opinion in rheumatology, [PMID:18388516] |
| 24. Polyak, Maria J MJ, Li, Haidong H, Shariat, Neda N and Deans, Julie P JP.. (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.. The Journal of biological chemistry, (4): [PMID:18474602] |
| 25. Niederfellner, Gerhard G and 16 more authors.. (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.. Blood, (14): [PMID:21444918] |
| 26. Ivaldi, Corinne C and 6 more authors.. (2012) Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.. PloS one, [PMID:22615937] |
| 27. Phuah, Jiayao J and 10 more authors.. (2016) Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.. Infection and immunity, [PMID:26883591] |
| 28. Hayashi, Kazumi and 6 more authors.. (2016) Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.. Cancer science, [PMID:26920337] |
| 29. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352] |
